Report

Monthly New Drug and First Time Generic February 2022



New Brand Drug Pipeline

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Celecoxib/Tramadol (Seglentis ®)	NSAID/Opioid Agonist	Pain	Anticipated March 2022.
Baclofen Oral Suspension (Fleqsuvy™)	Muscle Relaxant	Muscle Spasms	Launch pending. Approved February 4, 2022.
Baclofen Granules (Lyvispah™)	Muscle Relaxant	Muscle Spasms	Launch pending. Approved November 22, 2021.
Naloxone Injection (Zimhi™)	Opioid Antagonist	Opioid Overdose	Launch anticipated in 2022. Approved October 18, 2021.
Celecoxib Oral Liquid (Elyxyb™)	NSAID	Migraine Headache Treatment	Launch pending. Approved May 5, 2020.
Buprenorphine Depot Injection (Brixadi™)	Opioid Agonist	Treatment of Opioid Addiction	FDA review pending.
Oxycodone (Aximris XR™)	Opioid Analgesic – Extended Release	Pain	FDA review pending.
Nalmefene Injection	Opioid Antagonist	Opioid Overdose	FDA review pending.

Generic Pipeline

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Dabigatran (Pradaxa ®)	Anticoagulant	Treatment/Prophylaxis of Deep Vein Thrombosis	First patent set to expire December 2021. Generic anticipated June 2022.
Oxycodone HCl (Oxaydo ®)	Opioid Agonist	Pain	Generic exclusivity anticipated in 2022.
Apixaban (Eliquis ®)	Anticoagulant	Treatment/ Prophylaxis of Deep Vein Thrombosis	Generics approved December 23, 2019, but settlements expected to delay launch for at least a few years.
Diclofenac Potassium (Zipsor ®) Capsule	NSAID	Pain	Patent set to expire March 2022.

Report

Monthly New Drug and First Time Generic February 2022



Available in the Last 12 Months

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Naloxone Nasal Spray (Kloxxado™)	Opioid Antagonist	Opioid Overdose	August 2021
Newly Available Generics			
Naloxone HCl (Narcan ®) Nasal Spray	Opioid Antagonist	Opioid Overdose	December 2021
Zolmitriptan Nasal Spray (Zomig®)	Serotonin Agonist	Migraine Headache Treatment	November 2021
Nebivolol (Bystolic ®)	Beta Blocker	High Blood Pressure	September 2021
Ibuprofen/Famotidine (Duexis ®)	NSAID/H-2 Receptor Antagonist	Pain/Inflammation	August 2021
Pregabalin Extended Release (Lyrica [®] CR)	Anticonvulsant	Neuropathic Pain	April 2021
Hydrocodone Bitartrate (Hysingla™ ER)	Opioid Agonist – Extended Release	Pain	March 2021

Discontinuations & Withdrawals

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Hydrocodone ER Capsules (Zohydro ® ER)	Opioid Antagonist	Pain	Manufacturer has stopped distribution and FDA has rescinded approval effective February 2022.